Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Hologic features minimally invasive technologies at ACOG annual clinical meeting

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, is featuring minimally invasive technologies in surgical, diagnostic and skeletal health at The American College of Obstetricians and Gynecologists (ACOG) annual clinical meeting.

From Hologic, Inc. 7 May 2012

Hologic second quarter revenues increase 7.4% to $471.2 million

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the second fiscal quarter ended March 24, 2012.

From Hologic, Inc. 30 Apr 2012

Hologic enters definitive agreement to acquire Gen-Probe

Hologic, Inc. and Gen-Probe Incorporated today announced that their Boards of Directors have unanimously approved a definitive agreement under which Hologic will acquire all of the outstanding shares of Gen-Probe for $82.75 per share in cash, or a total enterprise value of approximately $3.7 billion.

From Hologic, Inc. 30 Apr 2012

New embolization procedure may bring hope to men with enlarged prostate

A new interventional radiology treatment, prostatic artery embolization, may bring hope to men with debilitating symptoms caused by an enlarged prostate, say the group of researchers who pioneered its use.

26 Mar 2012

Watson commences Esmya Phase 3 trial in women with anemia linked to uterine leiomyomas

Watson Pharmaceuticals, Inc. today announced it has initiated its Phase 3 trial to evaluate the efficacy and safety of Esmya (ulipristal acetate) in women with anemia associated with uterine leiomyomas, a medical condition often referred to as uterine fibroids (myomas). Leiomyomata are benign solid tumors that often lead to excessive menstrual bleeding, anemia and pain, which ultimately may require surgical intervention.

12 Mar 2012

Treatment with vitamin D reduces size of uterine fibroids

Treatment with vitamin D reduced the size of uterine fibroids in laboratory rats predisposed to developing the benign tumors, reported researchers funded by the National Institutes of Health.

2 Mar 2012

Hologic first quarter revenues increase 9.3% to $472.7 million

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the first fiscal quarter ended December 24, 2011.

From Hologic, Inc. 31 Jan 2012

InSightec seeks FDA premarket approval for ExAblate treatment of pain palliation of bone metastases

InSightec Ltd, the leader in MR guided Focused Ultrasound therapy, announced that it has submitted a premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for its ExAblate treatment of pain palliation of bone metastases.

24 Jan 2012

BU professor to study incidence of hypertension, diabetes and asthma in African American women

Patricia F. Coogan, ScD, an associate professor of epidemiology at Boston University's Slone Epidemiology Center (SEC), recently was awarded funding for two grants from the National Institutes of Health.

21 Dec 2011

Hologic receives FDA approval for Cervista HTA system to detect cervical cancer

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the U.S. Food and Drug Administration (FDA) has approved its Cervista HTA (high throughput automation) system for use with the Company's previously approved Cervista human papillomavirus (HPV) HR test.

From Hologic, Inc. 16 Dec 2011

Mayo Clinic becomes FUS Foundation's new Research Award recipient

The Focused Ultrasound Surgery Foundation has announced that its Research Awards Program is funding a Mayo Clinic study that will be the first to use U.S. commercial database information to compare the costs of three minimally-invasive treatments for symptomatic uterine fibroids, a benign and often debilitating condition that affects more than one in four American women.

30 Nov 2011

Hologic releases C-View synthesized 2D image reconstruction algorithm

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the commercial release of its C-View synthesized 2D image reconstruction algorithm that eliminates the need for a conventional 2D mammogram as a component of a tomosynthesis (3D mammography) breast cancer screening exam.

From Hologic, Inc. 28 Nov 2011

AAGL to showcase innovative surgical approaches, teaching tools at 40th Global Congress

Technology has radically changed the way surgeons practice medicine, and nowhere is this more evident than in the field of gynecologic endoscopy. AAGL, the oldest professional organization devoted to teaching minimally invasive treatment for women's health problems, will showcase a number of innovative surgical approaches and teaching tools among the hundreds of postgraduate courses and practice labs offered at its annual Global Congress, November 6-11, 2011 at the Westin Diplomat in Hollywood, FL.

19 Oct 2011

MR-guided focused ultrasound may effectively control essential tremor

In a presentation at the Congress of Neurological Surgeons today, University of Virginia neurosurgeon W. Jeffrey Elias, MD reported that preliminary results of a pilot clinical trial indicate that MR-guided focused ultrasound has the potential to safely and effectively control essential tremor (ET), a common neurological condition that affects 10 million Americans.

4 Oct 2011

Gynesonics initiates VizAblate FAST-EU study for uterine fibroid treatment

Gynesonics, Inc., a women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids, today announced the start of, and initial treatments in, the FAST-EU Trial, a multicenter clinical study to demonstrate the effectiveness of the VizAblate® procedure for the treatment of uterine fibroids associated with heavy menstrual bleeding.

22 Sep 2011

InSightec's ExAblate Neuro system may treat chronic brain disorders

InSightec Ltd., the global leader in MR guided Focused Ultrasound (MRgFUS) technology, announced today that its investigational ExAblate(R) Neuro system has been used in clinical studies to treat 30 patients suffering from chronic neurological disorders.

22 Sep 2011

'MRA Fusion' treatment for uterine fibroids

A radiologic technology, which functions like a 'human GPS system,' and provides more precise results while using less radiation, is being used to treat patients with symptomatic uterine fibroids exclusively at Paoli Hospital. Dr. Atul Gupta, director of interventional radiology, is treating patients as part of a first-ever clinical trial.

27 Jun 2011

Scientific evidence is key driver for gaining reimbursement for MR-guided focused ultrasound

Medical researchers have a critical role to play in gaining optimal health insurance reimbursement for MR-guided focused ultrasound. As Susan Klees, Director of Patient Access for the Focused Ultrasound Surgery Foundation, reports, "Scientific evidence is the key driver for reimbursement, and it all begins with the way studies are designed. Today, research priorities must be grounded in sound science as well as the realities of the marketplace."

24 Jun 2011

Hysterectomy procedures will continue to decline due to advantages of less-invasive alternatives: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, hysterectomy procedures as a treatment for menorrhagia and uterine fibroids will continue to decline at a rate of three percent a year through 2015. This decline is due to the growing advantages of less-invasive alternatives, primarily global endometrial ablation (GEA), and uterine artery embolization (UAE).

27 May 2011

Porter Adventist Hospital introduces new institute for robotic surgery

Robotic surgery, once the stuff of science fiction, has for some years been recognized as an important advance in surgical technique and patient experience. Now, at Porter Adventist Hospital, a comprehensive team of surgeons and staff are helping to bring in a new era in robotic surgery.

2 May 2011